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Abstract
Background: Leber’s Hereditary Optic Neuropathy (LHON; MIM 535000) is one of the most commonly inherited
optic neuropathies and it results in significant visual morbidity among young adults with a peak age of onset between
the ages of 15–30. The worldwide incidence of LHON is approximately 1 in 31,000. 95 % of LHON patients will have one
of 3 primary mitochondrial mutations, G3460A (A52T of ND1), G11778A (R340H of ND4) and T14484C (M64V of ND6).
There is incomplete penetrance and a marked gender bias in the development of visual morbidity with approximately
50 % of male carriers and 10 % of female carriers developing optic neuropathy. Visual recovery can occur but is
dependent on the mutation present with the highest level of visual recovery seen in patients who have the T14484C
mutation. The 3 primary mutations are typically identified by individual end-point PCR-restriction fragment length
polymorphism (RFLP) or individual targeted bi-directional Sanger sequencing reactions. The purpose of this study was
to design a simple multiplex PCR-RFLP that could detect these 3 primary LHON mutations in one assay.
Methods: PCR primers were designed to incorporate a MaeIII restriction site in the presence of 3460A and 14484C
mutations with the 11778A mutation naturally incorporating a MaeIII site. A multiplex PCR-RFLP assay was developed
to detect the 3 common mutations in a single assay. Synthetic LHON controls based on the mitochondrial genome
harbouring the 3 common mutations were synthesized and cloned into plasmids to act as reliable assay controls. DNA
from previously tested patients and the synthetic LHON controls were subjected to the multiplex PCR-RFLP assay. The
RFLP products were detected by agarose gel electrophoresis.
Results: The novel PCR-RFLP assay accurately detects the 3 primary mutations both in patient DNA and in synthesized
DNA control samples with a simple visual mutation detection procedure. The synthesized DNA was demonstrated to
be a robust control for the detection of LHON Mutations.
Conclusion: In this paper, we describe a novel, robust and simple PCR-RFLP based method for the detection of
mutations causing LHON, and report the generation of a series of LHON DNA controls suitable for all currently
published assays.
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Background
Leber’s hereditary optic neuropathy (LHON; MIM 535000)
is one of the most commonly inherited optic neuropathies
and it results in significant visual morbidity among young
adults [1, 2]. The disorder is the result of mitochondrial
dysfunction wherein primary mitochondrial DNA
(mtDNA) mutations affect complex I subunits of the re-
spiratory chain [3]. LHON is the most common among
primary mitochondrial diseases with a prevalence of 1 in
31,000 in the North of England, 1 in 39,000 in the
Netherlands and 1 in 50,000 in Finland [4–6]. In some
countries, approximately 95 % of individuals with LHON
have one of 3 primary mtDNA mutations; G3460A (A52T
of ND1), G11778A (R340H of ND4) and T14484C (M64V
of ND6) [3, 7, 8] while other rare mutations (such as
G13730A, G14459A, C14482G, A14495G, C14498T,
C14568Tand T14596A) account for the final 5 % [9–16].
LHON demonstrates marked gender bias and an incom-
plete penetrance, with approximately 50 % of males and
10 % of females who harbour one of the above mutations
actually developing optic neuropathy [17–19]. This indi-
cates that environmental or other genetic factors must play
a role in penetrance. Alcohol consumption, smoking,
certain prescription medications, stress and critical illness
have been implicated in the onset of symptoms in LHON
mutation carriers [17, 18, 20, 21].
The peak age of LHON onset is between 15–30 years
and 95 % of carriers who will experience visual failure will
do so before the age of 50 years [22]. However, visual de-
terioration can occur any time during the first to the
seventh decade of life [23]. Clinically, there tends to be an
acute loss of vision in one eye generally followed by loss of
vision in the other eye within 8 weeks. In the majority of
cases, LHON pathology is limited to a highly specialized
group of cells within the eye known as retinal ganglion
cells (RGCs). Histological analysis of the optic nerve in
LHON patients reveals minimal evidence of any inflam-
mation, but shows general axonal depletion centrally and
fibrocytic scarring. Any residual axons were limited to
superior and temporal peripheral clusters [24].
Visual recovery can occur in some LHON patients, but
the extent of which is influenced by the kind of mutation
involved in the development of a particular patient’s
LHON. The highest level of visual recovery is seen with
patients who have the T14484C mutation (up to 58 %),
followed by those with the G3460A mutation (up to
25 %). Patients who harbour the G11778A mutation have
the lowest level of visual recovery [25–28]. Thus, an ac-
curate mutation detection strategy can have a significant
prognostic value to the LHON patient.
Current diagnostic strategies for the 3 most common
mutations causing LHON include individual endpoint
PCR-RFLP [29], allele specific PCR [30], real time PCR [31]
and PCR followed by Sanger / pyrosequencing [32]. In this
study, we successfully designed a simple multiplex PCR-
RFLP to detect the 3 primary mitochondrial LHON muta-
tions and also describe the synthesis of a series of LHON
control sequences that act as a robust and patient-free re-
source for LHON test controls and assay development.
Methods
Patient DNA
Patient DNAs were obtained from the Centre for Med-
ical Genetics, Our Lady’s Hospital for Sick Children,
Dublin, Ireland and Oxford Medical Genetics Laborator-
ies, Oxford, UK. DNA was extracted from peripheral
blood using the Centra Puregene Blood Kit (Qiagen,
Manchester, UK) or the EZ1 Blood Kit on the EZ1
advanced XL instrument (Qiagen, Manchester, UK) ac-
cording to the manufacturers’ instructions. All samples
used in this study were previously tested for LHON
mutations using PCR amplification and DNA sequen-
cing. To maintain patient confidentiality during this
study, aliquots of residual DNA material from the
diagnostic test were labelled with the LHON mutation
detected and irreversibly anonymised. The use of patient
DNA in this study has received ethical approval from
the Dublin Institute of Technology Research Ethics
Committee (RN: 14–06).
Synthetic control DNA
To provide an unlimited, reliable and patient-free re-
source for LHON testing across all current testing plat-
forms as well as to allow for the development of the
multiplex PCR-restriction fragment length polymorph-
ism (RFLP) test described in this study, LHON control
sequences were synthesised and cloned into standard
plasmids by Eurofins Genomics (London, UK) or Life
Technologies (Carlsbad, USA) based on the reference se-
quence NC_012920.1. A total of 6 plasmids were gener-
ated containing the 3460G, 3460A, 11778G, 11778A,
14484 T and 14484C sequences. The 3460 plasmids con-
tained mitochondrial sequences from 3275 to 4272, the
11778 plasmids contained mitochondrial sequences from
11580 to 12118 and the 14484 plasmids contained mito-
chondrial sequences from 14449 to 15022 (Table 1). For
the generation of synthetic diagnostic controls, the plas-
mids were combined at a concentration of 1.5 ng/μl to
generate mixes containing none or one of the primary
LHON mutations as follows; Normal control that con-
tained no LHON mutations (a mix of 3460G, 11778G
and 14484 T plasmids at a concentration of 1.5 ng/μl),
3460A control that contained 3460A, 11778G and
14484 T plasmids, 11778A control that contained
3460G, 11778A, 14484 T plasmids, and 14484C control
that contained 3460G, 11778G, 14484C plasmids. This
information is summarised in Table 1.
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Primer design and PCR
Primers (Sigma Genosys, Arklow, Ireland) for the multi-
plex PCR-RFLP (Table 2) were designed to incorporate a
MaeIII (Roche, Burgess Hill, UK, Catalogue Number
10822230001) restriction site (↓GTnAC) in the presence
of 3460A and 14484C mutations. MaeIII was chosen be-
cause the 11778 mutation naturally introduces a MaeIII
restriction site and minor alterations of the PCR primers
as shown in Fig. 2a and Table 2, the 3460A and 14484C
mutations also introduce a MaeIII site to allow the de-
velopment of a multiplex PCR and RFLP strategy based
on the modified primers and MaeIII restriction enzyme.
The sequences of the PCR products highlighting the po-
sitions of the oligonucleotice primers and the MaeIII re-
striction sites are shown in the Additional files 1, 2 and
3. In Fig. 2a, alterations in the primer sequences leading
to the generation of a MaeIII site are shown in lower
case. Additionally, the 3460 PCR product contains a nat-
urally occurring MaeIII site at position 3736 to act as an
internal control of complete restriction in the assay. This
multiplex assay uses one PCR reaction and one restric-
tion enzyme thus allowing for a simple and cost effective
assay for the 3 common LHON associated mutations.
The primers produce products as follows: 3460 F/R
(333 bp), 11778 F/R (164 bp) and 14484 F/R (236 bp),
respectively. In the presence of the mutated allele, the
products change as follows: the 3460A mutation result-
ing in 279 bp, 28 bp and 26 bp (control of restriction),
11778A mutation producing 135 bp, 29 bp, and 14484C
mutation producing 205 bp, 31 bp, respectively. PCR
was performed in a reaction containing 50 ng of gen-
omic DNA (or 1 μl of the synthetic control described
above) using 1 unit of Platinum Taq polymerase (Life
Technologies, Carlsbad, USA, Catalogue Number
10966–034), 100 μM dNTP (Life Technologies, Carls-
bad, USA, Catalogue Number 10297–018), a primer mix
containing 250 ng of 3460 F/R, 60 ng of 11778 F/R and
40 ng of 14484 F/R and standard PCR buffer containing
3.5 mM MgCl2 (Life Technologies, Carlsbad, USA, Cata-
logue Number 10966–034). PCR conditions were 95 °C
for 5 min followed by 35 cycles of 95 °C for 30 s, 59 °C for
30 s and 72 °C for 30 s followed by a final extension at
72 °C for 5 min. Restriction with MaeIII was performed
using a reaction containing 12 μl of PCR product, 12.5 μl
of 2X MaeIII buffer and 0.5 μl (1 unit) of MaeIII for a
minimum of 2 h at 55 °C. Restriction products were de-
tected by electrophoresis on a 2.5 % agarose gel (Life
Technologies, Carlsbad, USA, Catalogue Number 16500–
100) containing 0.5 μg/ml ethidium bromide (Sigma
Genosys, Arklow, Ireland, Catalogue Number E7637).
Results
The workflow and expected results are presented sche-
matically in Fig. 1. As seen in Fig. 1, three PCR products
are generated in the multiplex reaction with sizes of
333 bp, 164 bp and 236 bp for the 3460, 11778 and
14484 products, respectively. Figure 1b demonstrates the
sizes of the restriction products generated from non-
mutated samples and the sizes of restriction products
generated from 3460, 11778 and 14484 mutated samples.
Figure 1c depicts schematically the expected results
from a diagnostic test on an agarose gel.
A range of patient DNA samples, non-mutated patient
DNA samples, and synthetic control samples were tested
in one assay using the multiplex PCR-RFLP as described
above. The sizes of restriction products expected are
Table 1 Synthetic LHON control plasmids and mixes
Plasmid Nucleotide Positions Normal Mix 3460A mix 11778A mix 14484C mix
3460G (N) 3275 – 4272 X X X
3460A (M) 3275 – 4272 X
11778G (N) 11580 – 12118 X X X
11778A (M) 11580 – 12118 X
14484 T (N) 14449 – 15022 X X X
14484C (M) 14449 – 15022 X
The table presents nucleotide positions, based on the reference sequence NC_012920.1, included in the cloned mitochondrial plasmids. 3460G indicates the
normal G nucleotide at position 3460 and 3460A indicates the mutated A at position 3460; similarly, for 11778 and 14484 plasmids. The synthetic diagnostic
control mixes are generated by mixing the indicated plasmids at 1.5 ng/μl. For a diagnostic test, 1 μl of a diagnostic control mix is used
Table 2 Primer sequences for multiplex PCR-RFLP
Mutation Forward Primer Reverse Primer Product Size
G3460A 5'-CCCCTACGGGCTACTACAACCCTTCGCTGtC 5'-GATAGTAGAATGATGGCTAG 333 bp
G11778A 5'-AGCAAACTCAAACTACGAACG 5'-TTACTAGCACAGAGAGTTCTC 164 bp
T14484C 5'-AATAGCCATCGCTGTAGTATATCCAAAGACAgtCA 5'-GTGCGAGAATAATGATGTATGC 236 bp
Lowercase letters indicate alterations introduced to the forward primers, which when in combination with the mutation, generate a MaeIII site. PCR product sizes
are indicated
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indicated in Table 3 and Fig. 1. The results of this ana-
lysis are presented in Fig. 2b. All patient DNA and syn-
thetic controls were genotyped by a blinded researcher
and were correctly genotyped using the assay. The natur-
ally occurring MaeIII site in the 3460 PCR product is used
as an internal control of restriction and removes 26 bp
from the PCR product. This can be seen between the un-
cut PCR product and the normal sample (lanes 2 and 3)
and demonstrates a complete restriction in all lanes. The
removal of the 26 bp from the 3460 PCR product
confirms complete restriction by MaeIII and assures ac-
curate mutation detection. The mutations are detected by
the MaeIII restriction with the removal of 28 bp, 29 bp
and 31 bp from the 3460, 11778 and 14484 PCR products,
respectively. In all cases, the identification of the presence
of a mutation is easily visualised on the 2.5 % agarose gel
(Fig. 2b). The patient controls and synthetic control sam-
ples behave identically indicating that the synthesized
DNA controls are a viable alternative to patient DNA for
controls.
Fig. 1 Workflow and expected results for the Multiplex PCR-RFLP. a: Sizes of PCR products generated in the multiplex PCR with products of 333 bp,
164 bp, and 236 bp. b: Size of restriction products generated by MaeIII restriction of the multiplex PCR products. In non-mutated samples, only the
internal control of restriction in the 3460 product is restricted resulting in the removal of 26 bp from the 333 bp PCR product. c: Schematic representation
of the band pattern expected from the diagnostic test. DNA samples with the 3460A, 11778A and 14484C mutations restricted with MaeIII yield the
restriction products indicated. The red arrow indicates the control of restriction and the yellow arrows indicate mutation detection
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As heteroplasmy is common with mitochondrial mu-
tations, a mutation detection strategy must be capable
of detecting heteroplasmy. Figure 3 presents an assay
on heteroplasmic 11778 samples with approximately
90 % 11778A and approximately 90 % 11778G, indi-
cating that the assay can accurately detect the presence
of heteroplasmy to a level of approximately 10 %.
Complete restriction of the naturally occurring MaeIII
site in the 3460 PCR product again assures that the
restriction is complete and that heteroplasmy was
accurately detected.
Discussion
This study aimed to develop a novel PCR-RFLP based
multiplex assay for the detection of the 3 common pri-
mary mutations leading to Leber hereditary optic neur-
opathy (LHON). Approximately 95 % of LHON patients
will have one of these 3 mutations, G3460A (13 %),
Table 3 PCR product and restriction product sizes expected in diagnostic test
1 2 3 4 5
Uncut PCR products MaeIII Non-mutated MaeIII 3460A MaeIII 11778A MaeIII 14484C
333 307 279 307 307
236 236 236 236 205
164 164 164 135 164
28 29 31
26 26 26 26
Column 1: PCR product sizes (bp) generated in the multiplex PCR. Column 2: Size of MaeIII restriction products obtained from non-mutated DNA samples. Column
3: Size of MaeIII restriction products obtained from 3460A samples. Column 4: Size of MaeIII restriction products obtained from 11778A samples. Column 5: Size of
MaeIII restriction products obtained from 14484C samples
Fig. 2 Multiplex PCR-RFLP. a: Diagram demonstrating the introduction of MaeIII restriction sites by the mutation (11778A) and the combination of primer
alterations and mutation (3460A, 14484C). Mutations are shown in red with the primer alterations in lower case. b: 2.5 % ethidium bromide stained
agarose gel showing the results of the PCR-RFLP on patient DNA (black labels) and synthesised DNA controls (red labels). DNA was PCR amplified in a
multiplex reaction using 3460 F/R, 11778 F/R and 14484 F/R and restricted using 1 unit of MaeIII as described. M: size marker; Uncut: non-restricted PCR
products; All other lanes: patient (Black) or synthesised DNA controls (Red) containing the indicated mutation PCR amplified and restricted with MaeIII.
The red arrow between the uncut and normal lanes demonstrates the internal control of restriction. Yellow arrows demonstrate mutation detection
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G11778A (69 %) and T14484C (14 %). In approximately
110 diagnostic tests conducted in Ireland, only the
11778A mutation has been detected (data not shown).
The PCR-RFLP approach was chosen because it provides
a simple, cost effective, robust and easy to read output
with minimal requirement for advanced technology. It
also allows the detection of all three primary mutations in
one multiplex analysis and allows the detection of hetero-
plasmy to a level of approximately 10 %. This is a signifi-
cant advantage over individual endpoint PCR-RFLP [29]
that requires 3 simplex PCRs followed by digestion with 3
separate restriction enzymes and electrophoresis. Allele-
specific PCR [30], either simplex that requires 3 separate
PCRs, or multiplex that requires only one PCR are effi-
cient, but will not detect heteroplasmy in currently pub-
lished formats. Individual real-time PCRs have been
reported [31], but require more advanced technologies
and are more costly. Individual endpoint PCR followed by
bidirectional Sanger/pyrosequencing require significantly
more hands-on time, and despite the decreasing costs of
sequencing, are still significantly more expensive than the
test reported here. As can been seen in Figs. 2b and 3, mu-
tation identification is clear and robust, both with patient
DNA and with the synthesised controls described above.
The genetic testing registry (http://www.ncbi.nlm.nih.
gov/gtr/) (accessed July 2015) shows that the vast majority
of LHON testing involves uni- or bi-directional Sanger
sequencing targeted to the 3 primary mutations (n = 20),
targeted simplex PCR-RFLP (n = 8), and other testing
methods (including real-time mutation detection, PCR
followed by hybridisation and pyrosequencing) (n = 4)
with 2 laboratories offering a targeted 37 mitochondrial
gene Next generation sequencing (NGS) panel (mtSEEK®).
PCR followed by Sanger/Pyrosequencing can be used for
LHON mutation detection, but requires individual PCRs
followed by individual sequencing reactions, and despite
decreasing costs for sequencing, still costs significantly
more than the test described in this study. NGS with ap-
propriate panels, will detect the 3 primary mutations [33]
but requires significantly more hands-on time for both set
up and bioinformatics analysis and, at present, is unlikely to
be used for the detection of known mutations due to the
costs involved and the simplicity of alternative tests. NGS
would, however, be invaluable in the detection of rarer /
unknown mutations post initial screening for the 3 primary
mutations and could be used for suspected LHON patients
negative for the primary mutation screen. The assay re-
ported in this study will allow diagnostic laboratories to
avoid costly NGS assays for the vast majority of LHON pa-
tients and allow resources to be focussed on patients with
unknown mutations requiring further analysis. We suggest
that the test described in this study will allow detection of
the 3 primary LHON mutations in a single test format at
minimal cost, with a rapid turnaround time and without
the need for advanced technology.
It is currently estimated that 35,000 individuals world-
wide are vision-impaired due to LHON. With the
addition of extended family members to this figure, there
is a significant requirement for a simple cost-effective
and robust diagnostic strategy for LHON mutation de-
tection. The steps required to obtain approval for this
diagnostic test for clinical applications include validation
of the strategy in larger scale trials in multiple laborator-
ies to ensure reproducibility and sensitivity/specificity
followed by applications to the national and inter-
national competent authorities such as FDA and EU
medical devices sections.
We also describe the generation of a series of con-
trols for LHON applicable for all currently described
LHON testing algorithms and demonstrate their ap-
plicability in this novel test. The generated controls
have also been tested in simplex PCR-RFLP (as described
in Marotta et al. 2004) and ARMS PCR (as described
in Bi et al. 2010) – data not shown. The controls will
provide an unlimited, reliable, and patient-free re-
source for LHON testing across all current testing
platforms. This resource may allow the development
of further tests in the future.
Conclusion
We developed a novel, cost-effective multiplex PCR-
RFLP based assay for the detection of the 3 most
common mutations causing LHON and demonstrated
the robustness of the assay in patient and synthetic
controls. The assay provides a significant advantage
over simplex PCR-RFLP and Sanger/pyrosequencing
approaches to mutation detection in terms of costs
Fig. 3 Detection of heteroplasmy using multiplex PCR-RFLP. 2.5 %
ethidium bromide stained agarose gel showing the results of the
multiplex PCR-RFLP on patient DNA heteroplasmic for G11778A
mutation. M: size marker; 11778A-1: patient sample approximately 90 %
11778A; 11778A-2: patient sample approximately 10 % 11778A
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and hands-on time required. A series of cloned
LHON and normal controls were developed and their
uses in this and other testing strategies confirmed.
This will be a useful resource for future test develop-
ment and diagnostic laboratories as it provides an un-
limited and patient-free source of control material.
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